Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC169096 in Advanced Solid Tumors
NCT05451602Phase 2Terminated
- Sponsor
- Sunshine Lake Pharma
- Start
- Oct 2022
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of HEC169096 in solid tumor, thyroid cancer, non-small cell lung cancer (NSCLC), sponsored by Sunshine Lake Pharma. Started Oct 2022; status: terminated.
02
Drugs
HEC169096
03
Conditions
solid tumorthyroid cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05451602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451602.